JP2011169913A5 - - Google Patents

Download PDF

Info

Publication number
JP2011169913A5
JP2011169913A5 JP2011098811A JP2011098811A JP2011169913A5 JP 2011169913 A5 JP2011169913 A5 JP 2011169913A5 JP 2011098811 A JP2011098811 A JP 2011098811A JP 2011098811 A JP2011098811 A JP 2011098811A JP 2011169913 A5 JP2011169913 A5 JP 2011169913A5
Authority
JP
Japan
Prior art keywords
fraction
lmwh
molecular weight
solvent
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011098811A
Other languages
English (en)
Other versions
JP2011169913A (ja
JP5186019B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011169913A publication Critical patent/JP2011169913A/ja
Publication of JP2011169913A5 publication Critical patent/JP2011169913A5/ja
Application granted granted Critical
Publication of JP5186019B2 publication Critical patent/JP5186019B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (27)

  1. 低分子量ヘパリン(LMWH)調製物を生成する方法であって、以下:
    第2のLMWHの画分を提供する工程であって、該第2のLMWHの画分は、第1の高分子量画分および該第2のLMWHの画分を生成する、溶媒中でのグリコサミノグリカン(GAG)含有サンプルの塩沈殿によって得られ、ここで、該第2のLMWHの画分は、該第1の高分子量画分から分離される、工程、ならびに
    該分離された第2の画分を処理して、濃縮されたLMWH調製物を生成する工程であって、ここで、該処理は、該第2の画分の酵素的消化である、工程
    を包含する、方法。
  2. 低分子量ヘパリン(LMWH)を生成する方法であって、以下:
    溶媒中でグリコサミノグリカン(GAG)含有サンプルの塩沈殿を実施して、第1の高分子量画分および第2のLMWHの画分を生成する工程、
    該第2のLMWHの画分から該第1の高分子量画分を分離する工程、ならびに
    該分離された第2の画分を処理して、濃縮されたLMWHを生成する工程であって、ここで、該処理は、該第2の画分の酵素的消化である、工程
    を包含する、方法。
  3. 前記方法が、溶媒を用いた前記第2のLMWHの画分の沈殿をさらに包含する、請求項2に記載の方法。
  4. 前記溶媒が、エタノール、ならびに、H Oとエタノールの組み合わせから選択される、請求項2に記載の方法。
  5. 前記GAG含有サンプルが、非分画ヘパリンである、請求項1または2に記載の方法。
  6. 前記塩沈殿が、二価のカチオンと弱アニオンの塩を用いて実施される、請求項1または2に記載の方法。
  7. 前記二価のカチオンの塩が、バリウム、カルシウム、マグネシウム、ストロンチウム、銅、ニッケル、カドミウム、亜鉛、水銀、ベリリウム、ニッケル、パラジウム、白金、鉄およびスズからなる群より選択される、請求項6に記載の方法。
  8. 前記二価のカチオンがカルシウムである、請求項6に記載の方法。
  9. 前記塩が酢酸カルシウムである、請求項1または2に記載の方法。
  10. 前記沈殿が、20℃〜1℃の範囲の温度において生じる、請求項1または2に記載の方法。
  11. 前記沈殿が、15℃〜5℃の範囲の温度において生じる、請求項10に記載の方法。
  12. 前記溶媒が、H O、H Oおよびエタノール、エタノール、H Oおよびアセトン、ならびにアセトンから選択される、請求項1または2に記載の方法。
  13. 前記溶媒がH Oおよびエタノールである、請求項12に記載の方法。
  14. 前記溶媒が、65:35〜35:65のH O:エタノール比を有する、請求項13に記載の方法。
  15. 前記溶媒が、55:45〜45:55のH O:エタノール比を有する、請求項14に記載の方法。
  16. 前記第2のLMWHの画分が、上清中に含まれる、請求項1または2に記載の方法。
  17. 前記第2の画分の平均分子量が、8000Daまたは8000Da未満である、請求項1または2に記載の方法。
  18. 前記第2の画分の平均分子量が、8000Da未満である、請求項1または2に記載の方法。
  19. 前記第2の画分が、8000Da未満の分子量を有する分子を少なくとも60%有する、請求項1または2に記載の方法。
  20. 前記第2のLWMHの画分が、ヘパリナーゼIIIで消化される、請求項1または2に記載の方法。
  21. 前記消化された第2のLWMH画分を精製または分離する工程をさらに包含する、請求項20に記載の方法。
  22. 前記消化された第2のLMWH画分を沈殿させる工程をさらに包含する、請求項20に記載の方法。
  23. 前記精製されたLWMH画分を、薬学的キャリアとともに処方する工程をさらに包含する、請求項21に記載の方法。
  24. 請求項1または2に記載の方法であって、前記第2のLWMHの画分が改変型ヘパリナーゼIIIで消化され、ここで、該改変型ヘパリナーゼIIIが、配列番号2の成熟ペプチドのアミノ酸配列を有するポリペプチドを含み、ここで、His36、His105、His110、His139、His152、His225、His234、His241、His424、His469およびHis539からなる群より選択される少なくとも1つのヒスチジン残基が置換されている、方法。
  25. 前記消化された第2のLWMH画分を精製または分離する工程をさらに包含する、請求項24に記載の方法。
  26. 前記消化された第2のLMWH画分を沈殿させる工程をさらに包含する、請求項24に記載の方法。
  27. 前記精製されたLWMH画分を、薬学的キャリアとともに処方する工程をさらに包含する、請求項25に記載の方法。
JP2011098811A 2000-09-12 2011-04-26 低分子量ヘパリンに関連する方法および生成物 Expired - Fee Related JP5186019B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23199400P 2000-09-12 2000-09-12
US60/231,994 2000-09-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002527786A Division JP4911865B2 (ja) 2000-09-12 2001-09-12 低分子量ヘパリンに関連する方法および生成物

Publications (3)

Publication Number Publication Date
JP2011169913A JP2011169913A (ja) 2011-09-01
JP2011169913A5 true JP2011169913A5 (ja) 2012-06-21
JP5186019B2 JP5186019B2 (ja) 2013-04-17

Family

ID=22871450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002527786A Expired - Fee Related JP4911865B2 (ja) 2000-09-12 2001-09-12 低分子量ヘパリンに関連する方法および生成物
JP2011098811A Expired - Fee Related JP5186019B2 (ja) 2000-09-12 2011-04-26 低分子量ヘパリンに関連する方法および生成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002527786A Expired - Fee Related JP4911865B2 (ja) 2000-09-12 2001-09-12 低分子量ヘパリンに関連する方法および生成物

Country Status (12)

Country Link
US (6) US7083937B2 (ja)
EP (2) EP1319183B1 (ja)
JP (2) JP4911865B2 (ja)
AT (1) ATE426805T1 (ja)
AU (1) AU2001292618A1 (ja)
CA (1) CA2422059C (ja)
CY (1) CY1110323T1 (ja)
DE (1) DE60138115D1 (ja)
DK (1) DK1319183T3 (ja)
ES (2) ES2640975T3 (ja)
PT (1) PT1319183E (ja)
WO (1) WO2002023190A2 (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6597996B1 (en) * 1999-04-23 2003-07-22 Massachusetts Institute Of Technology Method for indentifying or characterizing properties of polymeric units
ES2527853T3 (es) * 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinasa III y sus usos
EP1319183B1 (en) 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
AU2002362903A1 (en) * 2001-10-16 2003-04-28 Procognia, Ltd. Method of preparing purified biologically active oligosaccharide libraries
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
EP1551852A4 (en) * 2002-04-25 2007-03-21 Momenta Pharmaceuticals Inc METHOD AND PRODUCTS FOR MUCOSAL DELIVERY
AU2003303301B2 (en) * 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (en) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP4606712B2 (ja) 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
DE10315581B4 (de) * 2003-04-05 2007-06-28 Agilent Technologies, Inc. (n.d.Ges.d.Staates Delaware), Palo Alto Verfahren zur Qualitätsbestimmung von RNA-Proben
CN1886427B (zh) 2003-11-28 2012-05-23 伊士曼化工公司 纤维素共聚体和氧化方法
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US20060057638A1 (en) 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
US8101244B2 (en) 2004-06-09 2012-01-24 Smithkline Beecham Corporation Apparatus and method for producing or processing a product or sample
TWI356036B (en) 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
US20060002594A1 (en) * 2004-06-09 2006-01-05 Clarke Allan J Method for producing a pharmaceutical product
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
DE102005038418A1 (de) * 2005-08-12 2007-02-15 Dade Behring Marburg Gmbh Faktor Xa-basierter Heparinassay unter Verwendung einer Heparin-modifizierenden Komponente
US7767420B2 (en) 2005-11-03 2010-08-03 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2652205A1 (en) 2006-05-25 2007-12-06 Mallik Sundaram Low molecular weight heparin composition and uses thereof
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US7790466B1 (en) * 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
US20120238523A1 (en) * 2009-12-09 2012-09-20 Agency For Science, Technology And Research Glycosaminoglycan mixtures
EP2526122B1 (en) 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
JP5645493B2 (ja) * 2010-06-15 2014-12-24 川崎重工業株式会社 多糖類検査装置および多糖類検査方法
US9012168B2 (en) 2010-07-29 2015-04-21 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
AU2015203727B2 (en) * 2010-09-14 2016-05-26 Fuso Pharmaceutical Industries, Ltd. High Purity Heparin and Production Method Therefor
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
UA112070C2 (uk) * 2011-01-28 2016-07-25 Хангжоу Джіуюан Джін Енджініерінг Ко., Лтд Спосіб капілярного електрофорезу для аналізу тонкої структури еноксапарину натрію
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
WO2013116677A2 (en) * 2012-02-01 2013-08-08 Shire Human Genetic Therapies, Inc. Assays for detection of glycosaminoglycans
ES2445494B1 (es) * 2012-08-02 2015-03-06 Rovi Lab Farmaceut Sa Procedimiento de obtención de heparinas de bajo y muy bajo peso molecular
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
MX2022000343A (es) 2019-07-09 2022-03-11 Optimvia Llc Metodos para sintetizar polisacaridos anticoagulantes.
CN111019014A (zh) * 2019-11-22 2020-04-17 苏州二叶制药有限公司 一种那曲肝素钙的制备工艺
CN114264741B (zh) * 2021-12-15 2022-08-19 山东大学 一种鉴别猪来源肝素是否掺反刍类动物肝素的方法

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1390633A (en) * 1921-06-17 1921-09-13 Edgar A Milhaupt Bumper-bracket
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
US4551296A (en) 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
FR2554348B1 (fr) 1983-11-04 1987-01-23 Tissier Gerard Complexes hepariniques marques au moyen de radio-elements de vie courte emetteurs de radiations non ionisantes, leur procede d'obtention, les produits intermediaires et application de ces complexes
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
DK196986D0 (da) 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US4981955A (en) * 1988-06-28 1991-01-01 Lopez Lorenzo L Depolymerization method of heparin
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
PT93847A (pt) 1989-04-24 1990-11-20 Harvard College Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem
CA1340966C (en) 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (it) 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
US5284558A (en) 1990-07-27 1994-02-08 University Of Iowa Research Foundation Electrophoresis-based sequencing of oligosaccharides
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
JP3110064B2 (ja) 1991-03-06 2000-11-20 生化学工業株式会社 新規ヘパリチナーゼ、その製造法及びその生産菌
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
SK120193A3 (en) 1991-05-02 1994-07-06 Yeda Res & Dev Pharmaceutical composition for the prevention and/or treatment of pathological processes
WO1993005167A1 (en) 1991-09-06 1993-03-18 Children's Medical Center Corporation Cell-type specific heparan sulfate proteoglycans and their uses
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
EP0641438A1 (en) 1991-11-21 1995-03-08 Glyko, Inc. Fluorophore-assisted therapeutic drug monitoring
GB9202019D0 (en) 1992-01-30 1992-03-18 Imperial College Methods and apparatus for assay of sulphated polysaccharides
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
WO1993019734A1 (en) 1992-04-02 1993-10-14 Baker Norton Pharmaceuticals, Inc. Method and composition for treating antigen-induced and exercise-induced asthma
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (fr) 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US6770277B1 (en) * 1993-06-23 2004-08-03 Beckman Coulter, Inc. Recombinant DNase B derived from streptococcus pyogenes
JPH09508892A (ja) 1993-11-17 1997-09-09 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼを用いる血管形成の阻害方法
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US6376196B1 (en) * 1996-05-10 2002-04-23 The Regents Of The University Of California Recombinant neospora antigens and their uses
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
CA2189038A1 (en) 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (fr) 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
US5687090A (en) 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
EP0785774B1 (en) 1994-10-12 2001-01-31 Focal, Inc. Targeted delivery via biodegradable polymers
US5569366A (en) * 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
CA2222136C (en) 1995-05-26 2005-04-05 Bsi Corporation Method and implantable article for promoting endothelialization
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5690910A (en) 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5752019A (en) 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification
GB9606188D0 (en) 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
NZ332669A (en) 1996-04-29 1999-02-25 Dura Pharma Inc A dry power inhalation system which is flow rate independent
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU3892297A (en) 1996-07-26 1998-02-20 Ikonos Corporation Sensor for detecting heparin and other analytes
AU4055297A (en) * 1996-08-08 1998-02-25 William Marsh Rice University Macroscopically manipulable nanoscale devices made from nanotube assemblies
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
EP0954282B1 (en) 1997-01-16 2005-01-19 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6190875B1 (en) * 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6268146B1 (en) 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US7056504B1 (en) * 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000012726A2 (en) 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6597996B1 (en) 1999-04-23 2003-07-22 Massachusetts Institute Of Technology Method for indentifying or characterizing properties of polymeric units
ES2527853T3 (es) * 2000-03-08 2015-01-30 Massachusetts Institute Of Technology Heparinasa III y sus usos
EP1263932A4 (en) * 2000-03-14 2004-06-23 Es Cell Int Pte Ltd EMBRYONIC CELLS AND NEURONAL STEM CELLS DERIVED THEREFROM
US6373194B1 (en) * 2000-06-01 2002-04-16 Raytheon Company Optical magnetron for high efficiency production of optical radiation
EP1319183B1 (en) * 2000-09-12 2009-03-25 Massachusetts Institute Of Technology Methods and products related to low molecular weight heparin
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US6777244B2 (en) * 2000-12-06 2004-08-17 Hrl Laboratories, Llc Compact sensor using microcavity structures
US20020071457A1 (en) * 2000-12-08 2002-06-13 Hogan Josh N. Pulsed non-linear resonant cavity
AU2002306921A1 (en) 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
US6788847B2 (en) * 2001-04-05 2004-09-07 Luxtera, Inc. Photonic input/output port
US7248297B2 (en) * 2001-11-30 2007-07-24 The Board Of Trustees Of The Leland Stanford Junior University Integrated color pixel (ICP)
US6828786B2 (en) * 2002-01-18 2004-12-07 California Institute Of Technology Method and apparatus for nanomagnetic manipulation and sensing
AU2003303301B2 (en) * 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
WO2004055491A2 (en) 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (en) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
US6887773B2 (en) * 2002-06-19 2005-05-03 Luxtera, Inc. Methods of incorporating germanium within CMOS process
WO2004038874A2 (en) * 2002-09-27 2004-05-06 The Trustees Of Dartmouth College Free electron laser, and associated components and methods
US6922118B2 (en) * 2002-11-01 2005-07-26 Hrl Laboratories, Llc Micro electrical mechanical system (MEMS) tuning using focused ion beams
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
US7141800B2 (en) * 2003-07-11 2006-11-28 Charles E. Bryson, III Non-dispersive charged particle energy analyzer
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
US7851223B2 (en) * 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
WO2005087920A2 (en) 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
EP1582531A1 (en) * 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20060057638A1 (en) * 2004-04-15 2006-03-16 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US7586097B2 (en) * 2006-01-05 2009-09-08 Virgin Islands Microsystems, Inc. Switching micro-resonant structures using at least one director
US20060154894A1 (en) * 2004-09-15 2006-07-13 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20060187794A1 (en) * 2004-10-14 2006-08-24 Tim Harvey Uses of wave guided miniature holographic system
CA2594013A1 (en) * 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
WO2006089206A2 (en) 2005-02-16 2006-08-24 Massachusetts Institute Of Technology Methods to enhance carbon monoxide dehydrogenase activity and uses thereof
US20090105463A1 (en) 2005-03-29 2009-04-23 Massachusetts Institute Of Technology Compositions of and Methods of Using Oversulfated Glycosaminoglycans
WO2006105315A2 (en) 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions and methods for regulating inflammatory responses
US7619373B2 (en) * 2006-01-05 2009-11-17 Virgin Islands Microsystems, Inc. Selectable frequency light emitter
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum

Similar Documents

Publication Publication Date Title
JP2011169913A5 (ja)
CN104710525B (zh) 一种金枪鱼鱼骨胶原蛋白源锌螯合胶原肽及其制备方法和用途
CN100360036C (zh) 壳聚糖/金属铜复合抗菌剂的制备方法
Smidsrod et al. The molecular basis for some physical properties of polyuronides
WO2011054174A1 (zh) 低聚岩藻糖化糖胺聚糖及其制备方法
JP6432709B2 (ja) ポリ硫酸ペントサンの製造方法
RU2015116509A (ru) Способы и композиции для лечения рассеянного склероза и связанных с ним заболеваний
CN111019985B (zh) 一种酶解制备低分子量或寡聚透明质酸或其盐的方法
EP3233783A2 (en) Improved method for the synthesis of ferric oraganic compounds
WO2016041219A1 (zh) 一种糊精的分级方法
SI2794665T1 (en) Non-coagulating glycosaminoglycans containing a recurring disaccharide unit and their medical use
JP2016528262A5 (ja)
CN106636274B (zh) 一种米糠抗氧化活性肽的分离制备方法
US10889656B2 (en) Heparan sulfate having high 3-O-sulfation rate in glucosamine residues
JP2009057343A (ja) ナトリウム吸収阻害組成物
CN110604742A (zh) 杜仲多糖锶络合物及其制备方法和应用
JP2012219260A (ja) イオン液体を用いる甲殻類の甲殻又は貝類の貝殻からのキチンの製造方法
CN109485700B (zh) 一种血管紧张素转化酶ace抑制肽及其制备方法
Nøkling-Eide et al. Acid preservation of cultivated brown algae Saccharina latissima and Alaria esculenta and characterization of extracted alginate and cellulose
CN108359089B (zh) 一种抗菌性聚芳醚酮材料及其制备方法
JP6688432B2 (ja) 金属回収剤、金属化合物回収剤、及び、金属又は金属化合物の回収方法
JP2013516991A5 (ja)
CN1308351C (zh) 离子平衡交换法制备肝素锂
CN103804522A (zh) 一种提高肝素钠纯度的方法
JP2016517850A (ja) 水稲子実から組換えヒトラクトフェリンを分離精製する方法